9th Antigen-Specific Immune Tolerance Summit

Uniting 100+ leaders from cutting-edge biotechs to global pharma, this summit delivers comprehensive insight across antigen selection, biomarker strategy, B-cell and cellular tolerance mechanisms, delivery platforms, and clinical trial execution. The 2026 agenda spotlights late-stage data from Topas, Diamyd, and COUR; novel mRNA- LNP approaches from Moderna; integrated nanotherapeutics; and next-generation Treg and tolerance-restoring strategies. Key sessions explore central versus peripheral tolerance, and how gene and cell therapy are redefining therapeutic durability and safety. Now in its ninth year, the 9th Antigen-Specific Immune Tolerance Summit remains the only end-to-end meeting dedicated to advancing antigen-specific immune tolerance. Join Pfizer, Moderna, AbbVie, Diamyd, COUR, and others as the field transitions from discovery and preclinical efforts to real-world clinical impact. Seize the opportunity to and play a central role in rewriting these transformative therapeutics

Event Links

Website: https://go.evvnt.com/3346914-0

Tickets: https://go.evvnt.com/3346914-1

Brochure: https://go.evvnt.com/3346914-3

Read More

View Less